Actelion Sees Slower Growth Than Analysts From 2013 to 2015

Actelion Ltd. said earnings will remain stable in 2013 before rising in 2014 and accelerating to “double-digit” growth in 2015 as a new blood-pressure drug spurs sales.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.